Comparative Pharmacology
Head-to-head clinical analysis: VASCOR versus VERELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASCOR versus VERELAN.
VASCOR vs VERELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VASCOR (bepridil) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, reducing contractility and oxygen demand. It also has class I and IV antiarrhythmic properties.
Verapamil inhibits calcium ion influx across cardiac and smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and negative chronotropic, dromotropic, and inotropic effects.
Bepridil hydrochloride (Vascor) is typically dosed as 200 mg to 400 mg orally once daily.
Hypertension: 120-240 mg ER orally once daily; maximum 480 mg/day. Angina: 80-120 mg IR orally three times daily; ER 180-360 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal/hepatic function). May be prolonged in hepatic impairment; unchanged in renal impairment.
Terminal elimination half-life is 2.8 to 7.4 hours in healthy adults, prolonged in hepatic impairment or elderly (up to 12 hours).
Primarily hepatic metabolism; ~70% excreted in feces as metabolites, ~30% in urine (largely as metabolites). <2% excreted unchanged in urine.
Renal excretion accounts for approximately 70% of elimination, with 3-4% as unchanged drug. Fecal elimination accounts for about 25%, predominantly via biliary secretion.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker